This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

NK-001

Pivot Pharmaceuticals Inc.

Drug Names(s): etanercept

Description: NK-001 is a formulation of the drug Etanercept, being developed for a new indication, cognitive impairment (Etanercept is marketed under FDA approval as a treatment for rheumatoid arthritis and other rheumatoid/dermatologic indications).

Deal Structure: On June 17, 2008, Neurokine entered into a non-exclusive License Agreement with Globe Laboratories to use their developed know-how involving new techniques for the production of therapeutic proteins, including Etanercept, which forms the basis of NK-001 and NK-002.

Under the terms of the License Agreement, Neurokine was obligated to remit CAD$500,000 to Globe, comprised of a non-refundable license fee of CAD$150,000 (including CAD$50,000 in respect of patent preparation and filing fees) and a one-time royalty payment of CAD$350,000. In June 2008, Neurokine settled its obligation to Globe by issuing Globe 2,000,000 shares of its common stock.


NK-001 News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug